Tredje AP fonden reduced its stake in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 24.6% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 14,973 shares of the medical equipment provider’s stock after selling 4,897 shares during the quarter. Tredje AP fonden’s holdings in Zimmer Biomet were worth $1,513,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Dean Capital Management grew its stake in Zimmer Biomet by 1.3% during the 4th quarter. Dean Capital Management now owns 5,196 shares of the medical equipment provider’s stock valued at $778,000 after purchasing an additional 68 shares in the last quarter. Baird Financial Group Inc. lifted its holdings in shares of Zimmer Biomet by 0.3% in the 4th quarter. Baird Financial Group Inc. now owns 28,209 shares of the medical equipment provider’s stock worth $4,222,000 after purchasing an additional 72 shares during the last quarter. Trillium Asset Management LLC lifted its holdings in shares of Zimmer Biomet by 2.1% in the 1st quarter. Trillium Asset Management LLC now owns 4,085 shares of the medical equipment provider’s stock worth $413,000 after purchasing an additional 84 shares during the last quarter. Jones Financial Companies Lllp lifted its holdings in shares of Zimmer Biomet by 3.1% in the 1st quarter. Jones Financial Companies Lllp now owns 2,869 shares of the medical equipment provider’s stock worth $290,000 after purchasing an additional 86 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in shares of Zimmer Biomet by 0.7% in the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 13,245 shares of the medical equipment provider’s stock worth $1,983,000 after purchasing an additional 88 shares during the last quarter. Hedge funds and other institutional investors own 88.11% of the company’s stock.

In other news, insider Sang Yi sold 3,000 shares of Zimmer Biomet stock in a transaction on Friday, May 29th. The stock was sold at an average price of $125.38, for a total transaction of $376,140.00. Following the transaction, the insider now owns 2,506 shares in the company, valued at $314,202.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bryan C. Hanson purchased 1,000 shares of the stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average price of $113.00 per share, for a total transaction of $113,000.00. Following the acquisition, the chief executive officer now directly owns 54,568 shares of the company’s stock, valued at approximately $6,166,184. The disclosure for this purchase can be found here. Insiders own 0.44% of the company’s stock.

Shares of NYSE ZBH traded down $0.27 during mid-day trading on Friday, reaching $115.03. The company had a trading volume of 14,882 shares, compared to its average volume of 1,425,958. The company has a current ratio of 1.69, a quick ratio of 1.03 and a debt-to-equity ratio of 0.65. The stock has a market cap of $24.40 billion, a PE ratio of 63.70, a P/E/G ratio of 4.51 and a beta of 1.32. The company has a 50-day moving average price of $124.70 and a two-hundred day moving average price of $130.53. Zimmer Biomet Holdings Inc has a 1-year low of $74.37 and a 1-year high of $161.11.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Monday, May 11th. The medical equipment provider reported $1.70 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.53 by $0.17. The business had revenue of $1.78 billion for the quarter, compared to analysts’ expectations of $1.79 billion. Zimmer Biomet had a return on equity of 13.29% and a net margin of 4.84%. The company’s quarterly revenue was down 9.7% on a year-over-year basis. During the same period in the previous year, the firm posted $1.87 EPS. On average, research analysts expect that Zimmer Biomet Holdings Inc will post 3.82 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Monday, June 29th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.83%. The ex-dividend date is Friday, June 26th. Zimmer Biomet’s payout ratio is 12.20%.

Several brokerages recently issued reports on ZBH. Raymond James raised their price target on Zimmer Biomet from $136.00 to $140.00 and gave the stock a “strong-buy” rating in a report on Tuesday, May 12th. Evercore ISI downgraded Zimmer Biomet from an “outperform” rating to an “in-line” rating in a research note on Sunday, April 19th. UBS Group cut their target price on Zimmer Biomet from $180.00 to $165.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. Deutsche Bank cut their target price on Zimmer Biomet from $160.00 to $146.00 and set a “hold” rating on the stock in a research note on Tuesday, May 12th. Finally, SVB Leerink lifted their target price on Zimmer Biomet from $130.00 to $136.00 and gave the company an “outperform” rating in a research note on Tuesday, May 12th. Five investment analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and two have given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $147.72.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Featured Story: What are the advantages of the Stochastic Momentum Index?

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.